ALL MARKETS
FTSE 100
FTSE 250
AIM MARKET


Verona Pharma plc.
77 announcements.
Time Ticker Company Announcement
07:00 VRP Verona Pharma plc
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
07:00 VRP Verona Pharma plc
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
07:00 VRP Verona Pharma plc
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
14:33 VRP Verona Pharma plc
Holding(s) in Company TR-1: Standard form for notification of major holdings
09:35 VRP Verona Pharma plc
Verona Pharma plc: PDMR Dealing
07:00 VRP Verona Pharma plc
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
07:00 VRP Verona Pharma plc
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
07:00 VRP Verona Pharma plc
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
07:00 VRP Verona Pharma plc
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
07:00 VRP Verona Pharma plc
Verona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
07:00 VRP Verona Pharma plc
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
07:00 VRP Verona Pharma plc
Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference
11:07 VRP Verona Pharma PLC
PDMR Dealing
15:15 VRP Verona Pharma plc
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
12:51 VRP Verona Pharma plc
Result of AGM
07:00 VRP Verona Pharma plc
Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
07:00 VRP Verona Pharma plc
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
12:00 VRP Verona Pharma plc
Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
07:00 VRP Verona Pharma plc
Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
07:00 VRP Verona Pharma plc
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
12:07 VRP Verona Pharma plc
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
07:00 VRP Verona Pharma plc
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
07:00 VRP Verona Pharma plc
Grant of Options and RSUs and PDMR Dealings
07:00 VRP Verona Pharma plc
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
07:00 VRP Verona Pharma plc
PDMR Dealing
16:00 VRP Verona Pharma plc
2018 Annual Report and Accounts and Notice of AGM
07:00 VRP Verona Pharma plc
Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director
07:00 VRP Verona Pharma plc
PDMR Dealing
09:48 VRP Verona Pharma plc
PDMR Dealing
08:14 VRP Verona Pharma plc
PDMR Dealing
09:48 VRP Verona Pharma plc
PDMR Dealing
07:00 VRP Verona Pharma plc
Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
07:00 VRP Verona Pharma plc
Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
07:00 VRP Verona Pharma plc
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
07:00 VRP Verona Pharma plc
Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
07:00 VRP Verona Pharma plc
Verona Pharma to Present at Upcoming Investor Conferences
07:00 VRP Verona Pharma plc
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
13:00 VRP Verona Pharma plc
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
17:20 VRP Verona Pharma plc
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
07:00 VRP Verona Pharma plc
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
07:00 VRP Verona Pharma plc
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
07:00 VRP Verona Pharma plc
Verona Pharma Completes Enrollment in Phase 2 C...
06:00 VRP Verona Pharma plc
Verona Pharma to Announce Interim Results for N...
10:12 VRP Verona Pharma plc
Data from Clinical and Pre-Clinical Trials Eval...
07:00 VRP Verona Pharma plc
Verona Pharma to Host Investor & Analyst R&D Fo...
16:49 VRP Verona Pharma plc
Issue of Shares & PDMR Announcement
13:00 VRP Verona Pharma plc
Verona Pharma to Host Conference Call to Review...
07:00 VRP Verona Pharma plc
Verona Pharma to Present Expanded Dataset from ...
07:00 VRP Verona Pharma plc
Verona Pharma Announces Publication of Key Pap...
12:12 VRP Verona Pharma plc
Verona Pharma plc : PDMR Dealing & Issue of Shares
07:00 VRP Verona Pharma plc
Verona Pharma plc Operational Update and Financ...
07:00 VRP Verona Pharma plc
Verona Pharma Initiates Phase 2 Clinical Trial ...
13:30 VRP Verona Pharma plc
Verona Pharma plc : Notice of Results
13:30 VRP Verona Pharma plc
Verona Pharma to Present at 2018 Wedbush PacGro...
17:22 VRP Verona Pharma plc
Verona Pharma plc : Result of General Meeting o...
07:00 VRP Verona Pharma plc
Verona Pharma's Shelf Registration Statement de...
07:00 VRP Verona Pharma plc
Verona Pharma plc : Block Listing Update
13:30 VRP Verona Pharma plc
Verona Pharma to Present at Upcoming Investor C...
07:00 VRP Verona Pharma plc
Verona Pharma Files Shelf Registration Statemen...
07:03 VRP Verona Pharma plc
Verona Pharma Presented Clinical Data at ATS 20...
12:35 VRP Verona Pharma plc
Verona Pharma Provides Clinical Development Update
13:45 VRP Verona Pharma plc
Verona Pharma to Announce Operational Update an...
07:00 VRP Verona Pharma plc
Verona Pharma plc ("Verona Pharma" or the "Comp...
07:00 VRP Verona Pharma plc
Verona Pharma Reports Positive Top-Line Data fr...
16:40 VRP Verona Pharma PLC
Second Price Monitoring Extn
16:35 VRP Verona Pharma PLC
Price Monitoring Extension
13:38 VRP Verona Pharma plc
Verona Pharma plc : 1st Quarter Results
14:24 VRP Verona Pharma plc
Verona Pharma plc : Grant of Options and RSUs a...
17:30 VRP Verona Pharma plc
Verona Pharma plc: 2017 Annual Report and Accou...
12:00 VRP Verona Pharma plc
Verona Pharma to Present at Upcoming Healthcare...
07:00 VRP Verona Pharma plc
Verona Pharma Reports Positive Top-Line Data fr...
07:00 VRP Verona Pharma plc
Verona Pharma Announces Departure of Chief Medi...
13:30 VRP Verona Pharma plc
Verona Pharma to Announce Operational Update an...
08:31 VRP Verona Pharma plc
Verona Pharma plc : Result of AGM
13:30 VRP Verona Pharma plc
Verona Pharma to Present at Bio€quity Euro...
07:00 VRP Verona Pharma plc
Verona Pharma plc Operational Update and Financ...
13:30 VRP Verona Pharma plc
Verona Pharma plc : Miscellaneous